GlassScriptPhysician profile
Willis Lyford
NPI 1760877633
$1,335.60
in general payments reported to CMS, 2019-2025
14 companies · $596 in 2025
The $596 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.05 · 2023: $167 · 2024: $487 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $268.77 | 2024 | Ycanth |
| Sun Pharmaceutical Industries INC. | $258.44 | 2023-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $189.56 | 2023-2025 | |
| Ucb, INC. | $124.26 | 2024 | Bimzelx |
| Galderma Laboratories, L.P. | $109.31 | 2025 | Nemluvio |
| Janssen Biotech, INC. | $93.61 | 2023-2025 | Tremfya |
| Stemline Therapeutics INC. | $86.05 | 2019 | |
| Incyte Corporation | $55.60 | 2025 | Opzelura |
| Organon LLC | $36.78 | 2025 | Vtama |
| Leo Pharma INC. | $27.28 | 2023 | Adbry |
| Regeneron Healthcare Solutions, INC. | $26.06 | 2023 | Libtayo |
| Pfizer INC. | $21.63 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.74 | 2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $17.51 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willis Lyford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.